

CITATION REPORT

List of articles citing

Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections

DOI: 10.2147/idr.s236026

Infection and Drug Resistance, 2020, 13, 761-771.

Source: <https://exaly.com/paper-pdf/76990393/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211011373	2.8	4
2	Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections. <i>Drugs</i> , 2021 , 81, 377-388	2.8	9
1	A Phase 3, Multicenter, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infections. 2022 ,		